Hou Qing, Sun Bochen, Yao Ningning, Liang Yu, Cao Xin, Wei Lijuan, Cao Jianzhong
Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, China.
Cancers (Basel). 2022 Oct 7;14(19):4906. doi: 10.3390/cancers14194906.
Prophylactic cranial irradiation (PCI), as an essential part of the treatment of limited-stage small-cell lung cancer (LS-SCLC), inevitably leads to neurotoxicity. This study aimed to construct a brain metastasis prediction model and identify low-risk patients to avoid PCI; 236 patients with LS-SCLC were retrospectively analyzed and divided into PCI (63 cases) and non-PCI groups (173 cases). The nomogram was developed based on variables determined by univariate and multivariate analyses in the non-PCI group. According to the cutoff nomogram score, all patients were divided into high- and low-risk cohorts. A log-rank test was used to compare the incidence of brain metastasis between patients with and without PCI in the low-risk and high-risk groups, respectively. The nomogram included five variables: chemotherapy cycles (ChT cycles), time to radiotherapy (RT), lactate dehydrogenase (LDH), pro-gastrin-releasing peptide precursor (ProGRP), and lymphocytes−monocytes ratio (LMR). The area under the receiver operating characteristics (AUC) of the nomogram was 0.763 and 0.782 at 1 year, and 0.759 and 0.732 at 2 years in the training and validation cohorts, respectively. Based on the nomogram, patients were divided into high- and low-risk groups with a cutoff value of 165. In the high-risk cohort, the incidence of brain metastasis in the non-PCI group was significantly higher than in the PCI group (p < 0.001), but there was no difference in the low-risk cohort (p = 0.160). Propensity score-matching (PSM) analysis showed similar results; the proposed nomogram showed reliable performance in assessing the individualized brain metastasis risk and has the potential to become a clinical tool to individualize PCI treatment for LS-SCLC.
预防性颅脑照射(PCI)作为局限期小细胞肺癌(LS-SCLC)治疗的重要组成部分,不可避免地会导致神经毒性。本研究旨在构建脑转移预测模型并识别低风险患者以避免PCI;对236例LS-SCLC患者进行回顾性分析,分为PCI组(63例)和非PCI组(173例)。根据非PCI组单因素和多因素分析确定的变量构建列线图。根据列线图得分临界值,将所有患者分为高风险和低风险队列。采用对数秩检验分别比较低风险和高风险组中接受和未接受PCI患者的脑转移发生率。列线图包括五个变量:化疗周期(ChT周期)、放疗时间(RT)、乳酸脱氢酶(LDH)、胃泌素释放肽前体(ProGRP)和淋巴细胞-单核细胞比值(LMR)。训练队列和验证队列中列线图的受试者工作特征曲线下面积(AUC)在1年时分别为0.763和0.782,在2年时分别为0.759和0.732。根据列线图,将患者分为高风险和低风险组,临界值为165。在高风险队列中,非PCI组的脑转移发生率显著高于PCI组(p<0.001),但在低风险队列中无差异(p=0.160)。倾向评分匹配(PSM)分析显示了相似的结果;所提出的列线图在评估个体化脑转移风险方面表现可靠,有潜力成为LS-SCLC患者PCI个体化治疗的临床工具。